MedTrace Logo

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

NCT00139360 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2015-08-27

No results posted yet for this study

Summary

To determine the efficacy as measured by objective tumor response of first-line treatment of metastatic melanoma with bevacizumab monotherapy

Conditions

Interventions

DRUG

Bevacizumab

Anti angiogenesis treatment

Sponsors & Collaborators

  • Norwegian Cancer Society

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Oddbjorn Straume, MD, PhD · Department of Oncology, Haukeland University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139360 on ClinicalTrials.gov